artimist: thomson reuters "the ones to watch"

By Ben Comer | Published: March 22, 2011

Other drugs to keep an eye on, according to Thomson Reuters' The Ones to Watch report, include Phase 3 treatments such as ArTiMist, a malaria drug developed by Star Medical and Eastland Medical Systems, ChimeriVax Dengue, a Sanofi Pasteur drug for dengue virus infection, and Merck's V-212, for chickenpox and shingles, among others. The report, published in February, covered new drug approvals and pipeline candidates through then end of December, 2010.


http://blog.pharmexec.com/2011/03/22/thomson-reuters-names-top-new-drug-approvals-two-face-setbacks-in-the-us/